{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:58:12Z","timestamp":1740149892479,"version":"3.37.3"},"reference-count":14,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T00:00:00Z","timestamp":1517529600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aim<\/jats:title><jats:p>To prospectively evaluate long term outcomes in a cohort of patients with Systemic sclerosis treated with Hematopoietic stem cell transplant (HSCT).<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>This is a prospective observational study of four <jats:styled-content style=\"fixed-case\">SS<\/jats:styled-content>c patients who underwent <jats:styled-content style=\"fixed-case\">HSCT<\/jats:styled-content> at a tertiary care center in India between 2008\u20132012. The selection criteria included young individuals with rapidly progressive disease and at least one major organ involvement. We used granulocyte colony\u2010stimulating factor for peripheral blood stem cell mobilization, pre\u2010transplant conditioning with fludarabine, cyclophosphamide and rabbit anti\u2010thymocyte globulin followed by re\u2010infusion of autologous stem cells as per standard institute protocol.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of four patients (one male and three females) underwent autologous <jats:styled-content style=\"fixed-case\">HSCT<\/jats:styled-content> for <jats:styled-content style=\"fixed-case\">SS<\/jats:styled-content>c. Patients had heterogeneous disease manifestations including severe Raynaud's phenomenon with vasculopathic ulcers, gastrointestinal problems and mild interstitial lung disease (<jats:styled-content style=\"fixed-case\">ILD<\/jats:styled-content>). Patients were followed up for a mean duration of 7\u00a0years. There was significant sustained improvement in skin score, vasculopathy and gastrointestinal manifestations. Interstitial lung disease did not show any deterioration. The quality of life indices showed remarkable improvement in all subjects. No complications related to transplant were noted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In absence of an effective pharmacotherapy for <jats:styled-content style=\"fixed-case\">SS<\/jats:styled-content>c, autologous <jats:styled-content style=\"fixed-case\">HSCT<\/jats:styled-content> has a huge potential in management of cutaneous and internal organ manifestations.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1756-185x.13262","type":"journal-article","created":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T07:28:45Z","timestamp":1517556525000},"page":"859-865","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Stem cell transplant in systemic sclerosis: An Indian experience"],"prefix":"10.1111","volume":"21","author":[{"given":"Velu","family":"Nair","sequence":"first","affiliation":[{"name":"Internal Medicine &amp; Haematology Armed Forces Medical College Pune India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5001-189X","authenticated-orcid":false,"given":"Vivek","family":"Vasdev","sequence":"additional","affiliation":[{"name":"Rheumatology &amp; Clinical Immunology Army Hospital R &amp; R New Delhi India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7883-5118","authenticated-orcid":false,"given":"Abhishek","family":"Kumar","sequence":"additional","affiliation":[{"name":"Rheumatology &amp; Clinical Immunology Army Hospital R &amp; R New Delhi India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subramanian","family":"Shankar","sequence":"additional","affiliation":[{"name":"Rheumatology Command Hospital (Air Force) Bengaluru India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivek","family":"Nair","sequence":"additional","affiliation":[{"name":"Dermatology Maulana Azad Medical College New Delhi India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay","family":"Sharma","sequence":"additional","affiliation":[{"name":"Rheumatology &amp; Clinical Immunology Army Hospital R &amp; R New Delhi India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,2,2]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)64864-7"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.bor.0000434669.32150.ac"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.60.6.577"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.011205"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780230510"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.071464"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110868"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60982-3"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60982-3"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-eular.1962"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055120"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200702-326OC"},{"key":"e_1_2_6_14_1","unstructured":"ClinicalTrials.gov: Scleroderma: cyclophosphamide or transplantation (SCOT). Available from [cited 11 November 2017.]http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00114530?term+SCOT+trial& rank=6."},{"key":"e_1_2_6_15_1","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1182\/blood.V100.5.1602.h81702001602_1602_1610","article-title":"High\u2010dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes","volume":"100","author":"McSweeney PA","year":"2002","journal-title":"Blood"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1756-185X.13262","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185X.13262","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T15:15:56Z","timestamp":1695568556000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1756-185X.13262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,2]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["10.1111\/1756-185X.13262"],"URL":"https:\/\/doi.org\/10.1111\/1756-185x.13262","archive":["Portico"],"relation":{},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"type":"print","value":"1756-1841"},{"type":"electronic","value":"1756-185X"}],"subject":[],"published":{"date-parts":[[2018,2,2]]},"assertion":[{"value":"2018-02-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}